Cargando…

Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study

Aims: To explore differences in advanced brain magnetic resonance imaging (MRI) characteristics between myelin oligodendrocyte (MOG) immunoglobulin (IgG) and aquaporin-4 (AQP4) IgG seropositive (+) neuromyelitis optica spectrum disorders (NMOSD). Methods: 33 AQP4-IgG and 18 MOG-IgG seropositive NMOS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Felix A., Chien, Claudia, Kuchling, Joseph, Bellmann-Strobl, Judith, Ruprecht, Klemens, Siebert, Nadja, Asseyer, Susanna, Jarius, Sven, Brandt, Alexander U., Scheel, Michael, Paul, Friedemann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554609/ https://www.ncbi.nlm.nih.gov/pubmed/33101166 http://dx.doi.org/10.3389/fneur.2020.499910

Ejemplares similares

Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2018)

Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders
por: Motamedi, Seyedamirhosein, et al.
Publicado: (2020)

AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2021)

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients
por: Pache, Florence, et al.
Publicado: (2016)

Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study
por: Chien, Claudia, et al.
Publicado: (2019)

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica
por: Duan, Tianjiao, et al.
Publicado: (2018)

MOG-expressing teratoma followed by MOG-IgG-positive optic neuritis
por: Wildemann, Brigitte, et al.
Publicado: (2020)

Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder
por: Tradtrantip, Lukmanee, et al.
Publicado: (2021)

Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain
por: Saadoun, Samira, et al.
Publicado: (2014)

CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica
por: Tradtrantip, Lukmanee, et al.
Publicado: (2019)

Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders
por: Ringelstein, Marius, et al.
Publicado: (2021)

Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands: About one in a million
por: Daniëlle van Pelt, E, et al.
Publicado: (2016)

HLA association in MOG-IgG– and AQP4-IgG–related disorders of the CNS in the Dutch population
por: Bruijstens, Arlette L., et al.
Publicado: (2020)

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
por: Gernert, Jonathan A., et al.
Publicado: (2022)

Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD
por: Schroeder-Castagno, Maria, et al.
Publicado: (2022)

A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG
por: Wang, Xiaojuan, et al.
Publicado: (2018)

Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity
por: Duan, Tianjiao, et al.
Publicado: (2019)

Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders
por: Lu, Angelo, et al.
Publicado: (2022)

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
por: Palace, Jacqueline, et al.
Publicado: (2019)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
por: Bollo, Luca, et al.
Publicado: (2021)

Paraneoplastic AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder Associated With Teratoma: A Case Report and Literature Review
por: Ikeguchi, Ryotaro, et al.
Publicado: (2021)

Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder
por: Schmetzer, Oliver, et al.
Publicado: (2021)

Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel
por: Brill, Livnat, et al.
Publicado: (2021)

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
por: Weinshenker, Brian G., et al.
Publicado: (2006)

Comparison of spontaneous brain activity revealed by regional homogeneity in AQP4-IgG neuromyelitis optica-optic neuritis versus MOG-IgG optic neuritis patients: a resting-state functional MRI study
por: Wang, Junqing, et al.
Publicado: (2017)

Free-water diffusion tensor imaging detects occult periependymal abnormality in the AQP4-IgG-seropositive neuromyelitis optica spectrum disorder
por: Kim, Minchul, et al.
Publicado: (2022)

Optical coherence tomography angiography helps distinguish multiple sclerosis from AQP4‐IgG‐seropositive neuromyelitis optica spectrum disorder
por: Liu, Chunxin, et al.
Publicado: (2021)

Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar
por: Kleiter, Ingo, et al.
Publicado: (2022)

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin
por: Jarius, Sven, et al.
Publicado: (2016)

Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder
por: Maillart, Elisabeth, et al.
Publicado: (2020)

MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder
por: dos Passos, Giordani Rodrigues, et al.
Publicado: (2018)

Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis Optica
por: Chihara, Norio, et al.
Publicado: (2013)

Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro
por: Takeshita, Yukio, et al.
Publicado: (2016)

MOG-IgG- versus AQP4-IgG-Positive Optic Neuritis in Thailand: Clinical Characteristics and Long-Term Visual Outcomes Comparison
por: Narongkhananukul, Chanomporn, et al.
Publicado: (2020)

Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder
por: Li, Zhichao, et al.
Publicado: (2023)

Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study
por: Stiebel-Kalish, Hadas, et al.
Publicado: (2017)

Neuromyelitis optica-IgG testing in an Indian cohort with neuromyelitis optica and related demyelinating disorders: Our experience
por: Unni, Narayanan, et al.
Publicado: (2013)

Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders
por: Juenger, Valentin, et al.
Publicado: (2020)

What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients
por: Hamid, Shahd H. M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_enhe5i8kg5ee7ut0f1vdgaj205